

STARSOURCE MULTITRADE LIMITED
(Formerly known as Chemo Pharma Laboratories Limited)
(CIN: L46900MH1942PLC003556)



Date: August 14, 2026

To,
Bombay Stock Exchange Limited
Department of Corporate Services,
25th Floor, P. J. Towers, Dalal Street,
Mumbai-400001

Script Id: 506365

ISIN: INE320M01019

Subject: Outcome of Board Meeting held on August 14, 2026.

Dear Sir / Madam,

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations, 2015, we wish to inform you that Board of Directors of the Company at their meeting held on Friday, August 14, 2026 at the Registered Office of the Company, inter alia, have considered and approved Un-Audited Standalone Financial Results of the Company for the quarter ended June 30, 2026.

In this regard, we are enclosing herewith:

1. Un-Audited Standalone Financial Results of the Company for the quarter ended June 30, 2026, along with Limited Review Report thereon.
2. Declaration/Disclosure regarding under Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The aforesaid information will also be available on website of the company.

The meeting commenced at 03:30 PM and concluded at 04:05 PM.

The same may please be taken on record.

Thanking You.
Yours Faithfully,

FOR Starsource Multitrade Limited
(Formerly known as Chemo Pharma Laboratories Limited)

Mehta Ruchit P.



RUCHIT MEHTA
Managing Director & Chief Executive Officer
DIN: 08810586

Registered Office: 5 - Kumud Apartment CHS Ltd, Karnik Road, Chikan Ghar, Kalyan, - 421301, India
Corporate Headquarter: 1016, North Plaza, Near D Mart, Motera, Ahmedabad- 380005, India
Ph: +91-22-22078381 / 82 | Fax: +91-22-22074294
Email: chemopharmalaboratorieslimited@gmail.com | www.starsourcemultitrade.com

Independent Auditor Review Report on Unaudited Standalone Financial Results for the quarter ended 30th June 2026, of STARSOURCE MULTITRADE LIMITED (Formerly known as CHEMO PHARMA LABORATORIES LIMITED) pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 (2) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended.

To,

The Board of Directors,

STARSOURCE MULTITRADE LIMITED

(Formerly known as CHEMO PHARMA LABORATORIES LIMITED)

1. We have reviewed the accompanying statements of unaudited IND-AS Financial Results of **STARSOURCE MULTITRADE LIMITED (Formerly known as CHEMO PHARMA LABORATORIES LIMITED)** ("the Company") for the quarter ended 30th June, 2026 ("The Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ("the Regulations").
2. This Statement which is the responsibility of the Company's Management and has been approved by the Board of Director's, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in compliance with Listing Obligations. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion in this quarter.

Basis for Qualified Conclusion:

During the course of our review, information available from the Annual Information Statement (AIS) of the Company indicated the existence of a Goods and Services Tax Identification Number (GSTIN) pertaining to the Company. Management, however, represented that the Company was not registered under the Goods and Services Tax laws and, accordingly, did not provide GST registration details, GSTR-1 returns, or other GST records for the period under review.

4. Based on our review conducted as stated above, except for the possible effects of the matter described in the Basis for Qualified Conclusion paragraph, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, prescribed under Section 133 of the companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S S R V & Associates

Chartered Accountants

Firm Reg. No.: 125901W



Vishnu Kant Kabra

Partner

M. No.: 403437

Place: Mumbai

Date: 14th August, 2026

UDIN: 26403437EJXH5U6424

STARSOURCE MULTITRADE LIMITED

(Formerly known as Chemo Pharma Laboratories Limited)

Reg Office:- 5, Kumud Apartment CHS Ltd, Karnik Road Chikan Ghar, Kalyan, Thane, KALYAN, Maharashtra, 421301

CIN: L46900MH1942PLC003556 Email: chemopharmalaboratorieslimited@gmail.com, Website:

www.starsourcemultitrade.com

STATEMENT OF STANDALONE Un-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

(Rs. In Thousands, except EPS)

Sr. No.	Particulars	Quarter Ended (Standalone)		Year ended (Standalone)	
		30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
		Un-Audited	Audited	Un-Audited	Audited
1	(a) Net Sales/Income from operations	745.85	0.00	0.00	5,256.56
	(b) Other Income	0.00	8.72	207.12	238.86
	Total Income (a+b)	745.85	8.72	207.12	5,495.42
2	Expenditure				
	(a) Cost of Material Consumed	0.00	0.00	0.00	0.00
	(b) Purchase of Stock in Trade	0.00	0.00	0.00	3,765.35
	(c) Changes in inventories	0.00	0.00	0.00	0.00
	(d) Employee Benefit Expense	288.00	216.00	240.60	888.60
	(e) Finance Cost	0.31	0.00	5.38	9.81
	(f) Depreciation & Amortization Expense	1.35	3.48	0.00	3.48
	(g) Other Expenses	246.35	502.20	1,18,011.79	1,19,377.10
	Total Expenditure (a+b+c+d+e+f+g)	536.01	721.69	1,18,257.77	1,24,044.34
3	Profit before Exceptional Items & Tax (1-2)	209.84	(712.97)	(1,18,050.65)	(1,18,548.92)
4	Exceptional Items	0.00	0.00	0.00	
5	Profit before Tax (3-4)	209.84	(712.97)	(1,18,050.65)	(1,18,548.92)
6	Tax Expenses				
	Current Tax				
	i) Income Tax related to current year	0.00	0.00	0.00	0.00
	ii) Income Tax of earlier years	0.00	0.00	0.00	0.00
	iii) Deferred Tax (Assets)/Liabilities	0.00	0.80	0.00	0.80
	iv) MAT Credit Entitlement	0.00	0.00	0.00	0.00
7	Profit/(loss) after tax for the period (before adjustment for Associate) (5-6)	209.84	(713.77)	(1,18,050.65)	(1,18,549.72)
8	Add : Share of (Profit)/Loss of Associate	0.00	0.00	0.00	0.00
9	Profit for the Period (after adjustment for Associate (7 + 8))	209.84	(713.77)	(1,18,050.65)	(1,18,549.72)
10	Other Comprehensive Income (OCI)				
	(a) Items not to be reclassified subsequently to profit and loss	0.00	0.00	0.00	0.00
	(b) Items to be reclassified subsequently to profit and loss	0.00	0.00	0.00	0.00
	(c) Income Tax Related to Item not to be reclassify	0.00	0.00	0.00	0.00
	(d) Income Tax Related to Item to be reclassify	0.00	0.00	0.00	0.00
11	Total Comprehensive Income (9+10)	209.84	(713.77)	(1,18,050.65)	(1,18,549.72)
12	Paid up Equity Share Capital (Face Value Rs. 10/- each)	15,000.00	15,000.00	15,000.00	15,000.00
13	Reserves excluding Revaluation Reserves as per Balance Sheet of previous accounting year	(2,019.16)	(2,229.00)	(1,604.65)	(2,129.34)
14	Earning Per Share (EPS) (par value of Rs. 10/- each)				
	Basic	0.14	(0.48)	(78.70)	(79.03)
	Diluted	0.14	(0.48)	(78.70)	(79.03)
	*Not Annualised				

Notes

- 1 The above audited financial results are reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14th August, 2026.
- 2 The Company has no reportable business segment. Hence, separate information for segment wise disclosure is given in accordance with the requirements of Ind AS (AS) 108 - "Segment Reporting" is not required.
- 3 These results have been prepared in accordance with the Indian Accounting Standard (referred to as "Ind AS") 34 - Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules as amended from time to time and considering going concern assumption.
- 4 The Statutory Auditors have carried out limited review of the Unaudited Results of the Company for the Quarter ended June 30, 2026.
- 5 The above financial results are extracted from the Audited Financial Statements of the Company, which are prepared in accordance with the Indian Accounting Standards ('Ind As') as prescribed under section 133 of the companies Act, 2013 read with relevant rules issued thereunder and considering going concern assumption.
- 6 The figures have been re-grouped / re-arranged / re-classified / re-worked wherever necessary to make them comparable.

For **Starsource Multitrade Limited**



Mehta Ruchit P.

Ruchit Mehta
(Managing Director)
DIN : 08810586

Place : Kalyan

Date : 14th August, 2026

**RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER ENDED
30th JUNE, 2026**

Rs. In Thousands

PARTICULARS	STANDALONE		
	UNAUDITED QUARTER ENDED 30.06.2026	UNAUDITED QUARTER ENDED 30.06.2025	AUDITED YEAR ENDED 31.03.2025
Reconciliation of Profit After Tax as reported earlier:			
Net Profit / (Loss) for the Period (as per AS)	-118050.65	(1,18,050.65)	(412.97)
Benefit / (Charge):			
Impact of Deferred Income (Government Grant) Amortized to Income		0.00	0.00
Impact of Fair Valuation of Financial Instruments		0.00	0.00
Impact of Actuarial Gain / Loss Taken OCI		0.00	0.00
Impact of Adjustment of Deferred Tax Income		0.00	0.00
Impact of Adjustment of MAT Credit Entitlement		0.00	0.00
Net Profit / (Loss) for the Period (as per AS)		(1,18,050.65)	(412.97)

For Starsource Multitrade Limited



Mehta Ruchit R.

Place : Kalyan
Date : 14th August, 2026

RUCHIT MEHTA
MANAGING DIRECTOR
DIN: 08810586

**OTHER INFORMATION- INTEGRATED FILING (FINANCIAL) -
FOR THE QUARTER ENDED 30TH JUNE 2026**

(In accordance with the SEBI circular no . SEBI/ HO/ CFD/CFD-PoD-2/CIR/P/185 dated
December 31, 2024)

Sr. No	Particulars	Remarks
1	B. Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc.	NOT APPLICABLE
2	C. Format for disclosing outstanding default on loans and debt securities	NOT APPLICABLE
3	D. Format for disclosure of related party transactions (applicable only for half yearly filings i.e. , 2nd and 4th quarter)	NOT APPLICABLE
4	E. Statement on impact of audit qualifications (for audit report with modified opinion) submitted along-with annual audited financial results (standalone and consolidated separately) (applicable only for annual filing i.e., 4th quarter)	NOT APPLICABLE

FOR STARSOURCE MULTITRADE LIMITED



Mehra Ruchit

Date : 14th August, 2026
Place : Kalyan

RUCHIT MEHTA
MD & CEO
DIN: 08810586

STARSOURCE MULTITRADE LIMITED
(Formerly known as Chemo Pharma Laboratories Limited)
(CIN: L46900MH1942PLC003556)



Date: August 14, 2026

To,
Bombay Stock Exchange Limited
Department of Corporate Services,
25th Floor, P. J. Towers, Dalal Street,
Mumbai-400001

Script Id: 506365

ISIN: INE320M01019


Sub: Declaration/Disclosure regarding under Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time read, we do hereby confirm, declare and certify that the financial statements do not contain any false, misleading statements of figures and do not omit material fact which may make the statement or figures contained therein misleading.

You are therefore requested to take on record the aforesaid information for your reference.

Thanking You.
Yours Faithfully,

FOR Starsource Multitrade Limited
(Formerly known as Chemo Pharma Laboratories Limited)





RUCHIT MEHTA
Managing Director & Chief Executive Officer
DIN: 08810586

Registered Office: 5 - Kumud Apartment CHS Ltd, Karnik Road, Chikan Ghar, Kalyan, - 421301, India
Corporate Headquarter: 1016, North Plaza, Near D Mart, Motera, Ahmedabad- 380005, India
Ph: +91-22-22078381 / 82 | Fax: +91-22-22074294
Email: chemopharmalaboratorieslimited@gmail.com | www.starsourcemultitrade.com